Cargando…
Dasatinib promotes TRAIL‐mediated apoptosis by upregulating CHOP‐dependent death receptor 5 in gastric cancer
Dasatinib, a tyrosine kinase inhibitor, has been approved for first‐line treatment of leukemia and has also been evaluated for use in numerous other cancers. However, its role in gastric cancer (GC) remains unclear. Therefore, the aim of this study was to investigate how dasatinib suppresses the gro...
| Autores principales: | , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
John Wiley and Sons Inc.
2018
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5929929/ https://www.ncbi.nlm.nih.gov/pubmed/29744288 http://dx.doi.org/10.1002/2211-5463.12404 |